SCHEMBL4469222

SCHEMBL4469222

CCC(CCBr)c1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 4/20 0.37
IDO1 P14902 2/20 0.36
TDO2 P48775 2/20 0.36
CYP3A4 P08684 2/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
KCNQ2 O43526 1/20 0.32
CNR2 P34972 1/20 0.32
ACHE P22303 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20098233 0.85 TAS1R3 (0.38) MC4RIDO1TDO2CYP3A4TSHR
SCHEMBL781961 0.84 TSHR (0.40) MC4RIDO1TDO2CYP3A4TSHR
SCHEMBL8070755 0.82 CYSLTR2 (0.42) MC4RALDH1A1MEN1KMT2ALMNA
SCHEMBL24351028 0.79 NR1I2 (0.42) IDO1TDO2ALDH1A1MEN1KMT2A
SCHEMBL21725468 0.79 NR1I2 (0.42) IDO1TDO2ALDH1A1MEN1KMT2A
SCHEMBL6527704 0.78 NISCH (0.40) MC4RIDO1TDO2CYP3A4TSHR
SCHEMBL7384471 0.77 MC4R (0.41) MC4RIDO1CYP3A4TSHRCYP2C9
SCHEMBL8722409 0.77 L3MBTL1 (0.40) MC4RIDO1TDO2CYP3A4TSHR
SCHEMBL17858417 0.77 CYP3A4 (0.38) MC4RIDO1TDO2CYP3A4TSHR
SCHEMBL4480822 0.76 POLB (0.45) MC4RIDO1TDO2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016132134-A1 THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS UNIVERSITY OF DUNDEE (GB) 2016-08-25 WO disclosed
EP-1740576-B1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
US-7211576-B2 Diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2007-05-01 US disclosed
EP-1740576-A1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES F. Hoffman-la Roche AG (CH) 2007-01-10 EP disclosed
WO-2005103034-A1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES F. HOFFMAN-LA ROCHE AG (CH) 2005-11-03 WO disclosed
US-20050239843-A1 Diaminothiazoles DING QINGJIE 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239843-A1 Diaminothiazoles CDK4, CDK2, CDK1 MC4R 1472/4885IDO1 3438/4885TDO2 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.